Late last week, Bausch & Lomb (B&L) announced a new effort to sell pSivida’s retinal products across the US. The goal is to provide best-in-class sales support to surgeons for the company’s extensive portfolio of retina products.

pSivida supplies its drug delivery devices Retisert and Vitrasert to B&L. Unfortunately, last year B&L got smacked by a distracting and encompassing law suit in its contact lens division and never got around to putting the feet on the street to boost sales for its retina products. That’s changing this year and should bode well for pSivida in coming quarters.

Granted, pSivida isn’t a household name yet nor is it able to pull down headlines in the US like Arrowhead Research’s purchase of Carbon Nanotechnologies. (RNI Contributing Editor Tim Harper has an insight piece here.) But it will be gaining visibility if it continues to lay down the base hits it has in recent months.

Here’s the latest.